Filing Flows › Interpace Biosciences (IDXG) › R&D spending
Interpace Biosciences (IDXG) R&D spending by quarter
Interpace Biosciences' R&D spending was $149K in Q2 2026 (second quarter 2026), -3% from Q1 2026. Over the last 7 quarters it ranged from $142K (Q4 2025) to $193K (Q4 2024).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $149K | -3% | -14% |
| Q1 2026 | $153K | +8% | -14% |
| Q4 2025 | $142K | -5% | -26% |
| Q3 2025 | $150K | -13% | — |
| Q2 2025 | $173K | -2% | — |
| Q1 2025 | $177K | -8% | — |
| Q4 2024 | $193K | — | — |
Q2 2026 at a glance
Interpace Biosciences, Q2 2026: revenue $9.1M (-1% year over year), operating margin 3.5%, net earnings $158K, operating cash flow $98K. The chart follows the revenue to costs, profit and cash.
Questions
What is Interpace Biosciences' R&D spending?
Interpace Biosciences' R&D spending was $149K in Q2 2026 (second quarter 2026), -3% from Q1 2026.
How has Interpace Biosciences' R&D spending changed?
Over the last 7 quarters it ranged from $142K (Q4 2025) to $193K (Q4 2024).